Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGEN
Previous Symbol
CUSIP75991610
Phone781-250-0111
Debt
Debt-to-Equity RatioN/A
Current Ratio2.06
Quick Ratio1.73
Price-To-Earnings
Trailing P/E Ratio78.75
Forward P/E Ratio74.41
P/E Growth4.49
Sales & Book Value
Annual Sales$141.24 million
Price / Sales16.87
Cash Flow$0.8198 per share
Price / Cash Flow66.26
Book Value$13.58 per share
Price / Book4.00
Profitability
EPS (Most Recent Fiscal Year)$0.69
Net Income$28.35 million
Net Margins12.61%
Return on Equity5.39%
Return on Assets4.31%
Miscellaneous
Employees476
Outstanding Shares43,860,000
Market Cap$2.51 billion
OptionableOptionable
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) announced its earnings results on Thursday, November, 1st. The biotechnology company reported $0.20 EPS for the quarter, topping the Zacks' consensus estimate of $0.18 by $0.02. The biotechnology company had revenue of $49.53 million for the quarter, compared to analysts' expectations of $46.69 million. Repligen had a return on equity of 5.39% and a net margin of 12.61%. Repligen's revenue for the quarter was up 35.4% compared to the same quarter last year. During the same period last year, the firm earned $0.15 EPS. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $0.71-0.75 for the period, compared to the Thomson Reuters consensus estimate of $0.71. The company issued revenue guidance of $191-194 million, compared to the consensus revenue estimate of $187.95 million.
What price target have analysts set for RGEN?
7 Wall Street analysts have issued 1 year price targets for Repligen's stock. Their forecasts range from $55.00 to $70.00. On average, they expect Repligen's share price to reach $60.25 in the next twelve months. This suggests a possible upside of 10.9% from the stock's current price. View Analyst Price Targets for Repligen.
What is the consensus analysts' recommendation for Repligen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.
What are Wall Street analysts saying about Repligen stock?
Here are some recent quotes from research analysts about Repligen stock:
- 1. According to Zacks Investment Research, "Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. " (12/13/2018)
- 2. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $2.1B, driven by peak sales in the protein, filtration and chromatography businesses of $55M, $348M and $94M, respectively. We utilize a 9% discount rate and 29% effective tax rate. This yields a market value of the firm of $2.1B, assuming roughly $100M in debt and $174M in cash as of mid-2019. Given the projected 44M shares outstanding as of mid-2019, this yields a price objective of roughly $49 per share." (9/26/2018)
Has Repligen been receiving favorable news coverage?
Media headlines about RGEN stock have been trending somewhat positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Repligen earned a news impact score of 2.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the immediate future.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI) and Crispr Therapeutics (CRSP).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)
- Mr. Jon K. Snodgres, CFO & Sec. (Age 52)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director of Investor Relations
- Mr. Stephen Tingley, VP of Sales
Who are Repligen's major shareholders?
Repligen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.16%), Vanguard Group Inc. (8.94%), Vanguard Group Inc (8.94%), Conestoga Capital Advisors LLC (4.43%), William Blair Investment Management LLC (3.11%) and Macquarie Group Ltd. (2.72%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which institutional investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Schroder Investment Management Group, Federated Investors Inc. PA, Summit Creek Advisors LLC, Russell Investments Group Ltd., Prudential Financial Inc., Kornitzer Capital Management Inc. KS and North Star Asset Management Inc.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which institutional investors are buying Repligen stock?
RGEN stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., Point72 Asset Management L.P., Conestoga Capital Advisors LLC, Ardevora Asset Management LLP, Laurion Capital Management LP and Macquarie Group Ltd.. View Insider Buying and Selling for Repligen.
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $54.32.
How big of a company is Repligen?
Repligen has a market capitalization of $2.51 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe.
What is Repligen's official website?
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (NASDAQ RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
